American Association For The Study Of Liver Diseases

Hepatitis C patients who receive a liver from a white donor have significantly more aggressive recurrent hepatitis than those who receive a liver from a black donor, researchers have found.. Researchers from Henry Ford Hospital in Detroit looked at 165 hepatitis C ...

The breakthrough, reported this week at the annual meeting of the American Association for the Study of Liver Diseases in Boston, is a step towards making livers big enough for transplants in humans.. "We are the first to engineer a whole liver ...

Tuesday, 2 November 2010, 9:15 am BOSTON, Nov. 1, 2010 /PRNewswire/ -- The final results of the RESPOND-2 trial demonstrated that combination therapy with Boceprevir yields higher sustained virologic response (SVR) rates for patients with hepatitis C virus (HCV) genotype 1 who ...

10/30/2010 Print E-mail Scientists who created functioning miniature livers say their success is an early, but important, advance in the quest to grow replacement human livers in the laboratory.. "We are excited about the possibilities this research represents, but must stress that ...

AST-120 Also Shown to Reduce Ammonia and Brain Swelling in Rat Model of Cirrhosis. Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus (itching) in patients with chronic liver disease. Patients treated with ...

Tuesday, November 3, 2009, 8:00 am Eastern Time in Boston, MA. In this clinical trial to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers treated patients - both treatment naive and experienced patients ...

INHX) announced today that a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th ...

Presentations to include SVR results from Study C208 exploring twice-daily telaprevir-based dosing regimen, final PROVE 3 results and additional sub-analysis of PROVE 1 and PROVE 2 in " VRTX) today announced that sustained virologic response (SVR) data from Study C208, which evaluated ...

HUDDINGE, Sweden, Medivir has today together with its partner Tibotec presented data from the ongoing phase IIa trial with TMC435350. TMC435350 is an investigational protease inhibitor, being developed by Tibotec in partnership with Medivir, for the treatment of hepatitis C virus (HCV). ...

Safety and Pharmacokinetic Results in Healthy Volunteers to be Presented at AASLD. Anadys Pharmaceuticals, Inc. announced today preliminary results of a Phase I clinical trial of ANA598 in healthy volunteers and finalization of the protocol for a Phase Ib trial of ANA598 ...

Topic: American Association For The Study Of Liver Diseases

Race Affects Hepatitis C Recurrence After Liver Transplant: Study

First whole human liver built in lab

Final Results of Clinical Trial on Boceprevir

Scientists Report Early Success in Growing Mini Liver in Lab

Ocera Therapeutics Presents Clinical Data Demonstrating AST-120 Relieves Pruritus in Patients with Liver Cirrhosis at the 60th Annual AASLD Meeting

Twice Daily Oral Medication Shows Promise in Treating Patients with Hepatitis C

Inhibitex Announces Data Presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)

Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting

Phase IIa data on TMC435350 in patients with hepatitis C now presented at the ongoing AASLD

Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients

From Around the Web

Video Gallery

Follow this Topic with...